Royalty Pharma PLC Class A

RPRX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
C%LOCK|sx&$LOCK|VzVgTGC

Royalty Pharma Earnings: Resounding Receipt Growth Caps Off Landmark Year

Royalty Pharma totaled $874 million in portfolio receipts for the fourth quarter, increasing its revenue by 18% year over year. The firm announced four recent royalty transactions worth up to $4.7 billion and provided fiscal 2026 guidance that includes a receipt growth midpoint of 5.5%.

Sponsor Center